Compare Vanguard High Dividend Yield ETF (VYM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard High Dividend Yield ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard High Dividend Yield ETF trades at $163, while State Street SPDR S&P Biotech ETF trades at $159.67. Which is the better fit depends on your goals.
| VYM | XBI | |
|---|---|---|
52-Week High | $167.03 | $169.55 |
52-Week Low | $137.47 | $93.43 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VYM trades at $163.52, down 0.43% on the day, with technical indicators showing a bearish bias amid neutral oscillators. The ETF's current price sits near key support at $163, with resistance at $164. Recent news highlights VYM's 16% YTD total return outperformance versus SPY, with analysts noting its attractive valuation at a forward P/E of 18.85x compared to SPY's 20-21x, offering a higher earnings yield and 2.20% dividend.
The outlook for VYM remains balanced with technical weakness offset by fundamental value. Investment opportunities include sector diversification with financials exposure benefiting from higher rates, while risks involve yield compression and market volatility. Analyst sentiment is mixed with recent upgrades citing valuation appeal, though technical trends suggest near-term caution.
XBI (SPDR S&P Biotech ETF) trades at $161.97, down 1.12% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF holds over 150 biotech companies, benefiting from strong M&A activity and positive clinical catalysts, though key financial ratios are not applicable for the fund structure. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic given sector tailwinds, but high volatility and concentration in small-cap biotech pose risks. The single analyst covering the ETF maintains a Hold rating, reflecting a neutral stance amid the sector's rally and inherent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
